Search Results

120 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 18

    Human precision-cut lung slices as a screening tool: increased throughput, cryopreservation, and detection of DNA adducts for next generation tobacco product evaluation

    BEHRSING H.P.(1); DESAI P.(1); AMIN K.(2); BALBO S.(3); HECHT S.S.(2); SHEEHAN D.(1); CASTRO N.(1); ALLEN D.(4)
    (1) Institute for In Vitro Sciences, Inc., Gaithersburg, MD, U.S.A.; (2) University of Minnesota, Division of Environmental Health Sciences, Minneapolis, MN, U.S.A.; (3) University of Minnesota, Department of Laboratory Medicine and Pathology, Minneapolis, MN, U.S.A.; (4) Integrated Laboratory Systems, Inc., Morrisville, NC, U.S.A.
    Human-relevant, in vitro/ex vivo assays are considered an ethical and economically viable manner by which to screen the many chemicals requiring hazard assessment, such as next generation tobacco product (NGTP) ingredients. Human precision-cut lung slices ...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 45

    Meta-analysis of two biomarkers of exposure of tobacco products

    AYALA-FIERRO F.(1); ELAMIN A.(2); FROST-PINEDA K.(3); JIN T.(3); PRASAD G.L.(3); SARKAR M.(4); SCHMIDT E.(3); VERRON T.(5)
    (1) ITG Brands LLC, Greensboro, NC, U.S.A.; (2) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (3) RAI Services Company, Winston-Salem, NC, U.S.A.; (4) Altria Client Services LLC, Richmond, VA, U.S.A.; (5) SEITA - Imperial Brands, Paris, France
    In the context of tobacco products, broadly two types of biomarkers exist, biomarkers of exposure (BoE) and biomarkers of potential harm (BoPH). BoE measure exposure to tobacco constituents, e.g. carbon monoxide (CO) and nicotine equivalents (NEQs). The ...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 33

    Quantitative risk assessment (QRA) indicates reduced risk potential for carcinogenic and non-carcinogenic effects of the aerosol of the next generation products (NGPs) compared to reference cigarettes

    AYALA-FIERRO F.(1); CZEKALA L.(2); SIMMS L.(2); RUDD K.(2); CAVA G.(2); STEVENSON M.(2)
    (1) ITG Brands LLC, Greensboro, NC, U.S.A.; (2) Imperial Brands PLC, Bristol, U.K.
    In order to understand the potential relative health risks of NGPs compared to cigarettes, we compared the relative risks of aerosols from tobacco-containing and tobacco-free NGPs to the smoke generated from a reference cigarette. Quantitative Risk ...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 36

    Use of ex vivo precision-cut lung slices as a screening tool for potential respiratory toxicity of e-liquids

    BEHRSING H.P.(1); SHEEHAN D.(1); AMIN K.(2); LEE K.M.(3); OLDHAM M.(4); RAABE H.(1)
    (1) Institute for In Vitro Sciences, Inc., Gaithersburg, MD, U.S.A.; (2) University of Minnesota, Minneapolis, MN, U.S.A.; (3) Altria Client Services, Richmond, VA, U.S.A.; (4) former Altria Client Services employee
    The Family Smoking Prevention and Tobacco Control Act gave the FDA regulatory authority over next generation tobacco products (NGTP) such as e-vapor products. E-vapor product liquids contain a variety of ingredient combinations that should be assessed for ...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 47

    Identification, discussion and recommendations for the optimal generation and use of in vitro genotoxicity assay data for tobacco and nicotine products

    DESAI P.(1); CURREN R.(1); MOORE M.M.(2)
    (1) Institute for In Vitro Sciences, Gaithersburg, MD, U.S.A.; (2) Ramboll Environ Inc., Little Rock, AR, U.S.A.
    The Institute for In Vitro Sciences is sponsoring a series of workshops to identify, discuss and develop recommendations for optimal scientific/technical approaches for utilizing in vitro regulatory genotoxicity assay data within and across tobacco and ...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 58

    A consortium approach for consumer-reported outcome measures to assess tobacco- and nicotine-containing products

    ACQUADRO C.(1) on behalf of the CORESTA CROM Task Force: AYALA-FIERRO F.(2); BLACK R.(3); CAHOURS X.(4); CHREA C.(5); CURTIN G.(6); GILES L.(7); McCAFFREY S.(3); PARK C.H.(8); PRASAD K.(9); SHERWOOD N.(10); SHIFFMAN S.(11); SMITH J.(6); SPIES E.(5)
    (1) Mapi Research Trust, Lyon, France; (2) ITG Brands, Greensboro, NC, U.S.A.; (3) Altria Client Services, Richmond, VA, U.S.A.; (4) SEITA - Imperial Brands, Paris, France; (5) Philip Morris Products S.A., Neûchatel, Switzerland; (6) RAIS, Winston-Salem, NC, U.S.A.; (7) JT Int'l SA, Genève, Switzerland; (8) KT&G Research Institute, Daejeon, Republic of Korea; (9) British American Tobacco, Southampton, U.K.; (10) Neil Sherwood Consulting, Commugny, Switzerland; (11) Pinney Associates, Pittsburgh, PA, U.S.A.
    In the tobacco space, consumer-reported outcome measures (CROM) are essential for understanding motivations, subjective effects, and behavior. Such measures have become particularly important with the advent of candidate modified risk tobacco products ...
  7. TSRC, Tob. Sci. Res. Conf., 2019, 73, abstr. 008

    Workshop series to identify, discuss and develop recommendations for the optimal generation and use of in vitro genotoxicity assay data for tobacco and nicotine products

    MOORE M.M.(1); CURREN R.(2)
    (1) Ramboll US Corporation, Little Rock, AR, USA; (2) Institute for In Vitro Sciences, Gaithersburg, MD, USA
    The Institute for In Vitro Sciences is sponsoring a series of workshops to identify, discuss and develop recommendations for optimal scientific/technical approaches for utilizing in vitro regulatory genotoxicity assay data within and across tobacco and ...